Rare disease leadership CANbridge is a China-focused biopharma with a strong emphasis on orphan diseases and targeted cancers, presenting opportunities to collaborate on rare disease programs, licensing, and distribution partnerships in the Chinese market.

Strategic partnerships Recent and ongoing collaborations with WuXi Biologics, Scriptr Global, and Baheal signal openness to co-development, licensing, and commercialization deals across geographies, especially for rare disease therapies.

Expanded product portfolio Launch activity for Hunterase, Livmarli, and Gau running in China, plus a growing pipeline including CAN103 and gene therapy initiatives, creating multiple entry points for distribution, patient access programs, and payer discussions.

China market access NDA acceptance and commercial launches in China indicate momentum with regulatory approvals, suggesting opportunities to support market access, pricing strategy, reimbursement navigation, and physician education programs.

Leadership and governance Strategic hires and board-level appointments, such as a non-executive director addition, reflect a maturing company structure that can be engaged for long-term partnerships, co-development funding, and strategic investments.